Nashville Biosciences
Leeland Ekstrom has a diverse work experience spanning from 2002 to the present. Leeland is currently the CEO & Co-founder of Nashville Biosciences, LLC, a company that provides consulting and analytic services to pharmaceutical, diagnostics, and life sciences companies. Previously, Leeland served as the COO & Co-founder of the same company from 2016 to 2021. Prior to their role at Nashville Biosciences, Leeland worked at Vanderbilt University Medical Center as the Managing Director of BioVU Partnerships from 2015 to 2018. Leeland also has experience at McKinsey & Company, where they held multiple positions, including Associate Principal, Engagement Manager, and Associate. Leeland's early career includes roles as a Research Assistant at Massachusetts General Hospital and Queen's University. Leeland also pursued a Ph.D. at MIT during this time.
Leeland Ekstrom began their education at Lord Elgin High School from 1993 to 1998. Then, they pursued a Bachelor of Science degree in Engineering Physics at Queen's University from 1998 to 2002. Following that, they attended Queen's University once again from 1999 to 2003, this time to earn a Bachelor of Science degree in Life Sciences. Lastly, Leeland Ekstrom pursued their highest level of education, obtaining a PhD in Health Science & Technology / Nuclear Engineering from the prestigious Massachusetts Institute of Technology. Leeland completed their PhD from 2003 to 2009.
This person is not in any offices
Nashville Biosciences
Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center, was created to harness the medical center's extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities housed within Vanderbilt University Medical Center, including BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications.